Immune targets and neoantigens for cancer immunotherapy and precision medicine.
about
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Secreted tumor antigens - immune biomarkers for diagnosis and therapy.Identification of KANSARL as the first cancer predisposition fusion gene specific to the population of European ancestry origin.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.TLR Agonists as Adjuvants for Cancer Vaccines.Precision Medicine.Resources for Interpreting Variants in Precision Genomic Oncology Applications.Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions.Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses.Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins.Elevated neutrophil-to-lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer.IL-2 and Beyond in Cancer Immunotherapy.Engineering mechanical microenvironment of macrophage and its biomedical applications.Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.Immunological-based approaches for cancer therapyImmune-checkpoint inhibitors for combating T-cell dysfunction in cancerGenerating antitumor immunity by targeted radiation therapy: Role of dose and fractionationPredicting T cell recognition of MHC class I restricted neoepitopesConstitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
P2860
Q33819820-7F9AA5B5-25DB-479D-B993-BBBC45C5B6F9Q37728639-DBD74DEF-3A46-415C-A880-C112CE7ADF88Q38685785-1D8CAD20-248A-489F-9D5E-BCB0CA4A676BQ39438407-BCCF6FEE-D578-4744-A0CE-AD14B607704DQ40053323-D2BB4051-E533-45E4-B8F4-DF82FC4939B6Q40068135-84B4FDD3-4E00-4FEE-BB6B-F6A9BD230270Q40991226-F63B0F19-8570-453B-B5F0-2B0A4A60D429Q41849636-72FCF1C4-A53C-41C4-9218-BAE1AF364100Q41997055-11B95AFB-C884-48C6-A2FB-0368C88AD736Q42350237-095CA497-0250-478C-B6BE-503FB9388236Q42363061-9202DC49-C97E-4645-8734-0320D8AF1B87Q42372848-CF2C2DE6-B1F1-4AEE-A3EC-4FF21FEAEA29Q45714797-CD49AD32-4244-4877-912F-D35CD9939161Q47103994-29DB1AEC-E7D7-43B7-86A6-F118D9D3CB98Q47144502-D992D26C-F29C-4DD3-87AD-BAE17807DD08Q47165844-C330CDCD-9B25-41E3-8983-618CF18F01AAQ50004232-EB24AFE1-6116-473F-B8A1-7AED73C4F5EFQ50046074-0CBFAC01-2745-4348-8D74-77D4028D7FB1Q50080885-75C81CF4-7B73-414F-A0DF-D92D951D424FQ50130464-644FB054-0769-48A0-A7A8-CB6FF983B7B2Q50423294-35C06DD8-E942-4CBB-91E9-C78B7E2B14ACQ52579555-43F450A2-6505-4C2A-A225-BED2D5EA57B5Q52683991-2427DFDD-E734-40C3-8190-A52A2A13124FQ54945263-FF43D2DC-50C6-4F2F-A1D7-F0A3009CE229Q55365966-615053DA-9111-43CA-B7AF-089F1701E494Q57168423-366A3478-5C09-47B9-8188-B1EB8E6D54FAQ57483931-55084690-4E95-4995-A95E-FC04BC4A28BAQ58119207-0B2E8423-3215-4C00-82F5-C02BCFDDB091Q58129532-62FC7194-210E-480D-AD67-42DBA3337CFAQ59128454-498CC929-5933-4947-B354-87D540E04644
P2860
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@en
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@nl
type
label
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@en
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@nl
prefLabel
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@en
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@nl
P2860
P356
P1433
P1476
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
@en
P2093
Helen Y Wang
Rong-Fu Wang
P2860
P2888
P356
10.1038/CR.2016.155
P577
2016-12-27T00:00:00Z
P6179
1035915915